Document Detail

Lercanidipine in the treatment of hypertension.
MedLine Citation:
PMID:  17341540     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To review the literature regarding the efficacy, tolerability, and utility of lercanidipine in the treatment of hypertension. DATA SOURCES: A search of the literature was performed using MEDLINE (1966-September 2006), EMBASE Drugs and Pharmacology (1980-September 2006), and Current Contents/Clinical Medicine (week 24, 2005-week 30, 2006). Package inserts from lercanidipine, nifedipine, felodipine, and amlodipine were also reviewed for comparison of adverse effects. STUDY SELECTION AND DATA EXTRACTION: Articles were limited to clinical trials, abstracts, and review articles published in English. DATA SYNTHESIS: Lercanidipine is a novel dihydropyridine (DHP) calcium-channel blocker indicated for the treatment of mild-to-moderate hypertension. Although it is not yet available in the US, lercanidipine has been utilized extensively in other countries. In 2 randomized controlled trials of approximately 400 patients with mild-to-moderate hypertension, lercanidipine showed efficacy similar to that of 2 other DHPs, felodipine and slow-release nifedipine, in significantly reducing systolic blood pressure and diastolic blood pressure (DBP) after 4 weeks. In a longer trial (12 mo), lercanidipine 10 mg/day led to normalized blood pressure in 49% of patients after 4 weeks. A postmarketing trial of 9050 patients corroborated the results observed in previous clinical trials, with 64% of patients achieving a DBP of less than 90 mm Hg and 32% attaining blood pressure control (<140/90 mm Hg). In elderly patients, lercanidipine was found comparable with lacidipine and nifedipine, showing similar decreases in DBP when compared with nifedipine (-18.3 vs -17.7 mm Hg, respectively). What distinguishes lercanidipine from other members of the DHP class is its lower incidence of adverse effects, particularly edema. One study showed that fewer patients withdrew secondary to adverse drug reactions in the lercanidipine (0.9%) and nifedipine (3.8%) group compared with the felodipine (4.5%) group. Lercanidipine has also shown efficacy similar to that of other antihypertensives, including atenolol, captopril, and losartan. CONCLUSIONS: Lercanidipine may be an option in the treatment of hypertension, as current literature suggests comparable antihypertensive efficacy and better tolerability. Further randomized, double-blind clinical trials must be conducted in order to clarify its position among other antihypertensive medications.
Cherylyn Beckey; Amber Lundy; Nahla Lutfi
Publication Detail:
Type:  Journal Article; Review     Date:  2007-03-06
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  41     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-14     Completed Date:  2007-05-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  465-73     Citation Subset:  IM    
College of Pharmacy, Nova Southeastern University, Palm Beach Gardens, FL 33410, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Calcium Channel Blockers / adverse effects,  pharmacokinetics,  therapeutic use
Clinical Trials as Topic
Dihydropyridines / adverse effects,  pharmacokinetics,  therapeutic use*
Hypertension / drug therapy*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Dihydropyridines; 100427-26-7/lercanidipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Universal versus selective iron supplementation for infants and the risk of unintentional poisoning ...
Next Document:  Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a sc...